Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSONAL HTN: Optimisation of Amlodipine for Hypertension
NCT06713785Phase 4Withdrawn
- Sponsor
- Queen Mary University of London
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of amlodipine in hypertension (HTN) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Difference in daytime ambulatory systolic blood pressure between baseline ABPM and post-titration ABPM at 1 year. Planned start Sep 2020; status: withdrawn.
02
Drugs
amlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06713785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713785.